My Florida Green, a prominent medical marijuana provider in Florida, is intensifying efforts to influence federal cannabis policy in 2025. With the federal classification of cannabis as a Schedule I substance under the Controlled Substances Act, despite its medical legalization in numerous states, the company seeks to bridge the gap between state and federal regulations.
Nick Garulay, CEO of My Florida Green, has been vocal about the challenges posed by the current federal stance on cannabis. He emphasizes the need for a cohesive policy that recognizes the medical benefits of cannabis, aligning federal laws with the realities of state-level legalization. Garulay’s concerns are amplified by recent legislative proposals in Florida, such as HB 555, which he warns could inadvertently open doors to recreational use without proper oversight.
At the federal level, the landscape is equally complex. The Drug Enforcement Administration (DEA) has delayed hearings on the Biden administration’s proposal to reschedule cannabis, pushing discussions into 2025. This delay underscores the sluggish pace of federal reform, leaving states and businesses in a state of uncertainty.
In response, My Florida Green is advocating for the passage of the Evidence-Based Drug Policy Act of 2025, introduced by Representatives Dina Titus and Ilhan Omar. This bill aims to ease federal research restrictions on cannabis and other Schedule I substances, facilitating scientific studies that could inform future policy decisions.
Furthermore, the company supports the establishment of federal testing and labeling standards for cannabis products, ensuring consistency and safety across state lines. This initiative aligns with broader industry efforts to create a standardized regulatory framework, as seen in the recent push by the Wine and Spirits Wholesalers of America for federal oversight of hemp-derived cannabinoid products.
Despite these efforts, the path to federal reform remains fraught with challenges. The cannabis industry faces operational hurdles due to the federal ban, including restrictions on transporting products across state lines and limited access to traditional banking services. Additionally, the political climate under President Trump’s administration presents uncertainties, with the GOP-led Congress showing little interest in cannabis reform.
Nevertheless, My Florida Green remains steadfast in its mission. By engaging with lawmakers, supporting research initiatives, and advocating for standardized regulations, the company aims to pave the way for a more coherent and supportive federal cannabis policy. As the debate continues, stakeholders across the industry will be watching closely to see how these efforts unfold in the coming months.